NorDiag ASA has successfully completed a clinical trial for its automated sample preparation solution tailored for use with the Roche COBAS® TaqMan® 48 Analyzer and COBAS® TaqMan® CT Test, v2.0.

NorDiag has fully automated the process from the primary urine tubes to the PCR in Roche K-carrier tubes. NorDiag`s `Bullet` instrument has the capacity to process up to 100 000 isolations per year.

The trial compared NorDiag`s automated sample preparation solution for sexually transmitted infections with AMPLICOR® CT/NG Specimen Preparation Kit manual sample preparation. The tests were run on the Roche COBAS® TaqMan® 48 Analyzer and used the COBAS® TaqMan® CT Test, v2.0. The overall results were passing the trial criterion with good margins.

`This is an important milestone for us since this is the backbone for our solution, allowing us to sell the NorDiag`s `Bullet` instrument to accounts for IVD use,` says Mårten Wigstøl, CEO in NorDiag.

Contact:
CEO Mårten Wigstøl, Phone: +47 91165775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.

Read the Notice in Norwegian here